297 related articles for article (PubMed ID: 33775895)
21. New concepts of resistance in the treatment of Helicobacter pylori infections.
Graham DY; Shiotani A
Nat Clin Pract Gastroenterol Hepatol; 2008 Jun; 5(6):321-31. PubMed ID: 18446147
[TBL] [Abstract][Full Text] [Related]
22. Antimicrobial susceptibility testing before first-line treatment for
Cosme A; Montes M; Ibarra B; Tamayo E; Alonso H; Mendarte U; Lizasoan J; Herreros-Villanueva M; Bujanda L
World J Gastroenterol; 2017 May; 23(18):3367-3373. PubMed ID: 28566898
[TBL] [Abstract][Full Text] [Related]
23. Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.
Sugimoto M; Yamaoka Y
Arch Immunol Ther Exp (Warsz); 2009; 57(1):45-56. PubMed ID: 19219527
[TBL] [Abstract][Full Text] [Related]
24. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials.
Wenzhen Y; Yumin L; Quanlin G; Kehu Y; Lei J; Donghai W; Lijuan Y
Intern Med; 2010; 49(12):1103-9. PubMed ID: 20558925
[TBL] [Abstract][Full Text] [Related]
25. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection.
Georgopoulos S; Papastergiou V
Expert Opin Pharmacother; 2021 Apr; 22(6):729-741. PubMed ID: 33131337
[No Abstract] [Full Text] [Related]
26. Helicobacter pylori therapy: a paradigm shift.
Graham DY; Dore MP
Expert Rev Anti Infect Ther; 2016 Jun; 14(6):577-85. PubMed ID: 27077447
[TBL] [Abstract][Full Text] [Related]
27. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance.
Smith SM; O'Morain C; McNamara D
World J Gastroenterol; 2014 Aug; 20(29):9912-21. PubMed ID: 25110421
[TBL] [Abstract][Full Text] [Related]
28. Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy).
Yousfi MM; El-Zimaity HM; Cole RA; Genta RM; Graham DY
Aliment Pharmacol Ther; 1996 Feb; 10(1):119-22. PubMed ID: 8871452
[TBL] [Abstract][Full Text] [Related]
29. A new look at anti-Helicobacter pylori therapy.
Chuah SK; Tsay FW; Hsu PI; Wu DC
World J Gastroenterol; 2011 Sep; 17(35):3971-5. PubMed ID: 22046084
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies.
Realdi G; Dore MP; Piana A; Atzei A; Carta M; Cugia L; Manca A; Are BM; Massarelli G; Mura I; Maida A; Graham DY
Helicobacter; 1999 Jun; 4(2):106-12. PubMed ID: 10382124
[TBL] [Abstract][Full Text] [Related]
31. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance.
Graham DY; de Boer WA; Tytgat GN
Am J Gastroenterol; 1996 Jun; 91(6):1072-6. PubMed ID: 8651150
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype.
Sugimoto M; Furuta T
World J Gastroenterol; 2014 Jun; 20(21):6400-11. PubMed ID: 24914361
[TBL] [Abstract][Full Text] [Related]
33. Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective?
Breuer T; Graham DY
Am J Gastroenterol; 1999 Mar; 94(3):725-9. PubMed ID: 10086658
[TBL] [Abstract][Full Text] [Related]
34. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections.
McMahon BJ; Hennessy TW; Bensler JM; Bruden DL; Parkinson AJ; Morris JM; Reasonover AL; Hurlburt DA; Bruce MG; Sacco F; Butler JC
Ann Intern Med; 2003 Sep; 139(6):463-9. PubMed ID: 13679322
[TBL] [Abstract][Full Text] [Related]
35. The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy.
Eisig JN; André SB; Silva FM; Hashimoto C; Moraes-Filho JP; Laudanna AA
Arq Gastroenterol; 2003; 40(1):55-60. PubMed ID: 14534667
[TBL] [Abstract][Full Text] [Related]
36. Systematic review: Would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced?
Baylina M; Muñoz N; Sánchez-Delgado J; López-Góngora S; Calvet X; Puig I
Helicobacter; 2019 Jun; 24(3):e12584. PubMed ID: 30990575
[TBL] [Abstract][Full Text] [Related]
37. How to treat Helicobacter pylori infection--should treatment strategies be based on testing bacterial susceptibility? A personal viewpoint.
de Boer WA; Tytgat GN
Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):709-16. PubMed ID: 8853263
[TBL] [Abstract][Full Text] [Related]
38. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications.
Gerrits MM; van Vliet AH; Kuipers EJ; Kusters JG
Lancet Infect Dis; 2006 Nov; 6(11):699-709. PubMed ID: 17067919
[TBL] [Abstract][Full Text] [Related]
39. Culture-Based Antimicrobial Susceptibility Testing for Helicobacter pylori.
Lehours P; Mégraud F
Methods Mol Biol; 2021; 2283():45-50. PubMed ID: 33765308
[TBL] [Abstract][Full Text] [Related]
40. Role of bismuth in improving Helicobacter pylori eradication with triple therapy.
Dore MP; Lu H; Graham DY
Gut; 2016 May; 65(5):870-8. PubMed ID: 26848181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
